comprehensive -WSS

comprehensive

author：entertainment 2025-08-11 07:59:17 - browse：41

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How climate

hotspot

WSS

FDA warns J&J's Abiomed: We will regulate your software

Kellogg’s is going to war over Mexico’s nutrition label rules

Hospital at home shows how to bring innovation to health care

DeSantis wants to import drugs. Biden’s FDA blasted his plan

The explosion of genetic testing requires a new approach

FDA struggles to regulate food additives, sometimes for decades

focus

comprehensive

knowledge

Apple is now the first public company to be valued at $3 trillion

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Wildfire smoke exposes gaps in outdoor worker protections

NIH confirmation hearing shows politicization of research

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: Michael J. Fox on progress in Parkinson's research

Hollywood unions extend contract negotiations for actors

STAT Summit: GSK CEO on pharma giant's new direction

Medicare details structure of new drug price negotiation program

Former Pear Therapeutics executives start new VC firm

hotspot

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Hospital at home shows how to bring innovation to health care

How climate

STAT Summit: Biotech founders on deal

As obesity drug market grows, telehealth companies court payers

PBMs are inflating the cost of generic drugs. They must be reined in

hotspot

focus

hotspot

explore